×

Once registered, you can:

  • - Read additional free articles each month
  • - Comment on articles and featured creative work
  • - Get our curated newsletters delivered to your inbox

By registering you agree to our privacy policy, terms & conditions and to receive occasional emails from Ad Age. You may unsubscribe at any time.

Are you a print subscriber? Activate your account.

Aleve moves to BBDO, Femstat-3 to Euro RSCG

Published on .

Completing the transition of Aleve and Femstat-3 brands from Procter & Gamble Co. to Roche and marketing partner Bayer Corp., advertising for the $35 million Femstat-3 account shifted to Euro RSCG Tatham from Leo Burnett Co., both Chicago, and $70 million Aleve to BBDO, Chicago, from D'Arcy Masius Benton & Bowles, New York. Also last week, Roche received FDA approval for prescription Femstat-1 with one-day treatment; however, Bristol-Myers Squibb Co. also won approval to market Vagistat-1 over the counter.

Copyright February 1997, Crain Communications Inc.

In this article:
Most Popular